$AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Joshua Cohen
CEO
123
Employees
$13.81
Current Price
$1.17B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 5 | 6 | $1,204,667.88 | 83,197 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 5 | 10 | $1,762,490.58 | 121,202 | ||
| 3 months | Buys | 1 | 1 | $100,845.00 | 8,100 | 1:56.78 |
| Sells | 5 | 17 | $5,726,293.91 | 416,313 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | Klee Justin B. Director | Sale | 29,282 | $14.47 | $423,760.32 | View Details |
| Mar 2, 2026 | Cohen Joshua B Director | Sale | 29,282 | $14.48 | $424,120.49 | View Details |
| Mar 2, 2026 | Bedrosian Camille L Chief Medical Officer | Sale | 6,461 | $14.58 | $94,205.26 | View Details |
| Mar 2, 2026 | FRATES JAMES M Chief Financial Officer | Sale | 7,909 | $14.52 | $114,851.33 | View Details |
| Mar 2, 2026 | Mazzariello Gina Chief Legal Officer | Sale | 6,844 | $14.52 | $99,378.30 | View Details |
| Feb 23, 2026 | Mazzariello Gina Chief Legal Officer | Sale | 3,419 | $14.14 | $48,352.18 | View Details |
| Feb 2, 2026 | FRATES JAMES M Chief Financial Officer | Sale | 3,557 | $14.65 | $52,096.89 | View Details |
| Feb 2, 2026 | Cohen Joshua B Director | Sale | 15,500 | $14.68 | $227,592.70 | View Details |
| Feb 2, 2026 | Mazzariello Gina Chief Legal Officer | Sale | 3,448 | $14.65 | $50,515.61 | View Details |
| Feb 2, 2026 | Klee Justin B. Director | Sale | 15,500 | $14.69 | $227,617.50 | View Details |
| Jan 16, 2026 | Cohen Joshua B Director | Sale | 1,974 | $13.83 | $27,299.04 | View Details |
| Jan 15, 2026 | Cohen Joshua B Director | Sale | 136,193 | $13.59 | $1,850,794.77 | View Details |
| Jan 15, 2026 | Klee Justin B. Director | Sale | 136,193 | $13.58 | $1,849,868.66 | View Details |
| Jan 16, 2026 | Klee Justin B. Director | Sale | 1,995 | $13.89 | $27,701.17 | View Details |
| Jan 6, 2026 | FRATES JAMES M Chief Financial Officer | Sale | 3,326 | $11.11 | $36,953.86 | View Details |
| Jan 6, 2026 | Cohen Joshua B Director | Sale | 7,715 | $11.09 | $85,596.38 | View Details |
| Jan 6, 2026 | Klee Justin B. Director | Sale | 7,715 | $11.09 | $85,589.44 | View Details |
| Dec 23, 2025 | Firestone Karen Director | Purchase | 8,100 | $12.45 | $100,845.00 | View Details |
15 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.30
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history